Current opinion on drug-induced oral reactions: A comprehensive review

Journal of Contemporary Dental Practice

Volumn 9, Issue 3, 2008, Pages 001-015

  Abdollahi, Mohammad ^a   Rahimi, Roja ^a   Radfar, Mania ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse drug effects; Drug reactions; Oral mucosal reactions; Oral reactions; Side effects

Indexed keywords

DRUG;

CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; JAW DISEASE; MOUTH DISEASE; MOUTH MUCOSA; REVIEW; TOOTH DISEASE;

HUMANS; JAW DISEASES; MOUTH DISEASES; MOUTH MUCOSA; PHARMACEUTICAL PREPARATIONS; TOOTH DISEASES;

EID: 40949121890     PISSN: None     EISSN: 15263711     Source Type: Journal    
DOI: 10.5005/jcdp-9-3-1     Document Type: Review

References (131)

1. Ciancio SG. Medications' impact on oral health. J Am Dent Assoc. 2004 Oct;135(10):1440-8.
2. Guggenheimer J. Oral manifestations of drug therapy. Dent Clin North Am. 2002 Oct;46(4):857-68.
3. Rees TD. Drugs and oral disorders. Periodontol 2000. 1998 Oct;18:21-36.
4. Smith RG, Burtner AP. Oral side-effects of the most frequently prescribed drugs. Spec Care Dentist 1994; 14(3):96-102.
5. Abdollahi M, Radfar M. A review of drug-induced oral reactions. J Contemp Dent Pract 2003, 4(1):10-31.
6. Moghadam BK, Drisko CL, Gier RE. Chlorhexidine mouthwash-induced fixed drug eruption; case report and review of the literature. Oral Surg Oral Med Oral Pathol. 1991; 71(4):431-434.
7. Alvarez Santullano CV, Tover Flores V, De Barrio Fernandez M, Tornero Molina P, Prieto Garcia A. Fixed drug eruption due to ibuprofen. Allergol Immunopathol (Madr). 2006, 4(6):280-1.
8. Rubegni P, Fimiani M. Images in clinical medicine. Bisphosphonate- associated contact stomatitis. N Engl J Med. 2006, 30;355(22):e25.
9. Jurge S, Kuffer R, Scully C, Porter SR. Mucosal disease series. Number VI. Recurrent aphthous stomatitis. Oral Dis 2006, 12(1):1-21.
10. Scully C. Clinical practice. Aphthous ulceration. N Engl J Med. 2006 Jul 13;355(2):165-72.
11. Koybasi S, Parlak AH, Serin E, Yilmaz F, Serin D. Recurrent aphthous stomatitis: investigation of possible etiologic factors. Am J Otolaryngol. 2006, 27(4):229-32.
12. Chakrabarty AK, Mraz S, Geisse JK, Anderson NJ. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. J Am Acad Dermatol 2005, 52(2 Suppl 1):35-7.
13. Zalaudek I, Petrillo G, Argenziano G. Aphthous ulcers and imiquimod. J Am Acad Dermatol 2005, 53(2):360-1.
14. Goker E, Rodenhuis S. Early onset of oral aphthous ulcers with weekly docetaxel. Neth J Med 2005, 63(9):364-6.
15. Vucicevic Boras V, Savage N, Mohamad Zaini Z. Oral aphthous-like ulceration due to tiotropium bromide. Med Oral Patol Oral Cir Bucal 2007, 12(3):E209-10.
16. Akintoye SO, Greenberg MS. Recurrent aphthous stomatitis. Dent Clin North Am 2005, 49(1):31-47.
17. Cerchiari DP, de Moricz RD, Sanjar FA, Rapoport PB, Moretti G, Guerra MM. Burning mouth syndrome: etiology. Rev Bras Otorrinolaringol (Engl Ed) 2006, 72(3):419-23.
18. Fedele S, Fricchione G, Porter SR, Mignogna MD. Burning mouth syndrome (stomatodynia). QJM 2007, 100(8):527-30.
19. Savage NW, Boras VV, Barker K. Burning mouth syndrome: clinical presentation, diagnosis and treatment. Australas J Dermatol 2006, 47(2):77-81.
20. Triantos D, Kanakis P. Stomatodynia (burning mouth) as a complication of enalapril therapy. Oral Dis 2004, 10(4):244-5.
21. Vlasses PH, Rotmensch HH, Ferguson RK, Sheafer SL. Scalded mouth caused by angiotensin converting enzyme inhibitors. B M J 1982, 284:1672-1673.
22. Savino L, Haushalter HM. Lisinopril-induced scalded mouth syndrome. Ann Pharmacother 1992, 26:1381-1382.
23. Brown RS, Krakow AM, Douglas T. Scalded mouth syndrome caused by angiotensin converting enzyme inhibitors: two case reports. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997, 83(6):665-667.
24. Culhane NS, Hodle AD. Burning mouth syndrome after taking clonazepam. Ann Pharmacother 2001, 35(7-8):874-876.
25. Palin SL, Kumar S, Barnett AH, Sturdee DW. A burning mouth associated with the use of hormone replacement therapy. J Br Menopause Soc 2005, 11(1):38.
26. Borras-Blasco J, Belda A, Rosique-Robles JD, Castera MD, Abad FJ. Burning mouth syndrome due to efavirenz therapy. Ann Pharmacother 2006, 40(7-8):1471-2.
27. Sardella A. An up-to-date view on burning mouth syndrome. Minerva Stomatol 2007, 56(6):327-40.
28. Litt JZ. Drug eruption reference manual. London, The Parthenon Publishing Group, 2001: 274-421.
29. Micromedex Healthcare Series, Drugdex, Drug Consults, 2007, Vol. 133.
30. Abdollahi M, Karimpour H, Khalaj S. Drug-induced skin reactions. J Pharm Pract Res 2003, 33(1):12-15.
31. Isik SR, Karakaya G, Erkin G, Kalyoncu AF. Multidrug-induced erythema multiforme. J Investig Allergol Clin Immunol 2007, 17(3):196-8.
32. Farthing P, Bagan JV, Scully C. Mucosal disease series. Number IV. Erythema multiforme. Oral Dis 2005, 11(5):261-7.
33. Scully C, Felix DH, Oral Medicine -Update for the dental practitioner. Mouth ulcers of more serious connotation. Br Dent J 2005, 199:339-343.
34. Dega H, Laporte JL, Frances C, Herson S, Chosidow O. Ginseng as a cause for Stevens-Johnson syndrome? Lancet 1996, 347(9011):1344.
35. Lin AY, Baker BA. Verapamil-associated Stevens-Johnson syndrome. DICP 1989, 23(12):987-988.
36. Hilas O, Charneski L. Lamotrigine-induced Stevens-Johnson syndrome. Am J Health Syst Pharm 2007, 1;64(3):273-5.
37. Scully C, Felix DH. Oral medicine - update for the dental practitioner. Aphthous and other common ulcers. Br Dent J 2005, 10;199(5):259-64.
38. McAvoy BR. Letter: Mouth ulceration and slow-release potassium tablets. Br Med J 1974, 19;4(5937):164-165.
39. Nordt SP. Tetracycline-induced oral mucosal ulcerations. Ann Pharmacother 1996, 30(5):547-548.
40. Drysdale SF, Phillips-Howard PA, Behrens RH. Proguanil, chloroquine, and mouth ulcers. Lancet 1990, 335(8682):164.
41. Wittkowsky AK, Reddy R, Bardy GH. Oral mucosal ulceration from disopyramide. Ann Pharmacother 1995, 29(12):1299-1300.
42. Vaillant L, Fontes V. Bullous diseases of the oral mucosa. Rev Prat 2002, 15;52(4):385-8.
43. Laeijendecker R, Dekker SK, Burger PM, Mulder PG, Van Joost T, Neumann MH. Oral lichen planus and allergy to dental amalgam restorations. Arch Dermatol 2004, 140(12):1434-8.
44. Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, Axell T, Bruce AJ, Carpenter W, Eisenberg E, Epstein JB, Holmstrup P, Jontell M, Lozada-Nur F, Nair R, Silverman B, Thongprasom K, Thornhill M, Warnakulasuriya S, van der Waal I. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 103(Suppl S25):1-12.
45. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci 2007, 49(2):89-106.
46. Almeyda J, Levantine A. Drug reactions. XVI. Lichenoid drug eruptions. Br J Dermatol 1971, 85(6):604-7.
47. Scully C, Felix DH, Oral Medicine - Update for the dental practitioner. Red and pigmented lesions. Br Dent J 2005, 199: 639-645.
48. Eisen D. Disorders of pigmentation in the oral cavity. Clin Dermatol 2000, 18:579-587.
49. Scully C. Discoloured tongue: a new cause? Br J Dermatol 2001, 144(6):1293-4.
50. Summitt JB, Robbins JW, Schwartz RS, Santos JD. Fundamentals of operative dentistry. 2nd ed., Chicago, Quintessence Publishing Co., 2001:402.
51. Aschheim KW, Dale BG. Esthetic dentistry, a clinical approach to techniques and materials. 2nd ed., Philadelphia, Mosby, 2001:247-249.
52. Tredwin CJ, Scully C, Bagan-Sebastian JV. Drug-induced disorders of teeth. J Dent Res 2005, 84(7):596-602.
53. McKenna BE, Lamey PJ, Kennedy JG, Bateson J. Minocycline-induced staining of the adult permanent dentition: a review of the literature and report of a case. Dent Update 1999, 26(4):160-162.
54. Korber A, Dissemond J. Images in clinical medicine. Black hairy tongue. N Engl J Med 2006, 5;354(1):67.
55. Tamam L, Annagur BB. Black hairy tongue associated with olanzapine treatment: a case report. Mt Sinai J Med 2006, 73(6):891-4.
56. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis 2006, 12(3):229-41.
57. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006, 14(6):505-15.
58. Sabater Recolons Mdel M, Lopez Lopez J, Rodriguez de Rivera Campillo ME, Chimenos Kustner E, Conde Vidal JM. Buccodental health and oral mucositis. Clinical study in patients with hematological diseases. Med Oral Patol Oral Cir Bucal 2006, 11(6):E497-502.
59. Kataoka M, Kido J, Shinohara Y, Nagata T. Drug-induced gingival overgrowth - a review. Biol Pharm Bull 2005, 28(10):1817-21.
60. Schincaglia GP, Forniti F, Cavallini R, Piva R, Calura G, del Senno L. Cyclosporin-A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro. J Oral Pathol Med 1992, 21(4):181-185.
61. Das SJ, Newman HN, Olsen I. Keratinocyte growth factor receptor is up-regulated in cyclosporine-A induced gingival hyperplasia. J Dent Res 2002, 81(10):683-687.
62. Myrillas TT, Linden GJ, Marley JJ, Irwin CR. Cyclosporin A regulates interleukin-1beta and interleukin-6 expression in gingiva: implications for gingival overgrowth. J Periodontol 1999, 70(3):294-300.
63. Soory M, Suchak A. The effects of human mast-cell products and of phenytoin on androgen 5alpha-reductase expression in human gingival fibroblasts. Arch Oral Biol 2001, 46(9):847-855.
64. Hassell TM, Burtner AP, McNeal D, Smith RG. Oral problems and genetic aspects of individuals with epilepsy. Periodontol 2000, 6:68-78.
65. Shimizu Y, Kataoka M, Seto H, Kido J, Nagata T. Nifedipine induces gingival epithelial hyperplasia in rats through inhibition of apoptosis. J Periodontol 2002, 73(8):861-867.
66. Rezaie S, Rezaie A, Minaiee B, Khorasani R, Abdollahi M. On the relation of nitric oxide to nifedipine-induced gingival hyperplasia and impaired submandibular glands function in rats in vivo. Fund Clin Pharmacol 2005, 19(1):65-711-7.
67. Fujimori Y, Maeda S, Saeki M, Morisaki I, Kamisaki Y. Inhibition by nifedipine of adherence- and activated macrophage-induced death of human gingival fibroblasts. Eur J Pharmacol 2001, 9;415(1):95-103.
68. King GN, Fullinfaw R, Higgins TJ, Walker RG, Francis DM, Wiesenfeld D. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J Clin Periodontol 1993, 20(4):286-293.
69. Camargo PM, Melnick PR, Pirih FQ, Lagos R, Takei HH. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontol 2001, 27:131-8.
70. Rezaie A, Khalaj S, Shabihkhani M, Nikfar S, Zamani MJ, Mohammadirad A, Daryani NE, Abdollahi M. Study on the correlations among disease activity index and salivary transforming growth factor-β1 and nitric oxide in ulcerative colitis patients. Ann NY Acad Sci 2007, 1095:305-314.
71. Rezaie A, Ghorbani F, Eshghtork A, Zamani MJ, Dehghan G, Taghavi B, Nikfar S, Mohammadirad A, Daryani NE, Abdollahi M. Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-β1 in relation to disease activity in Crohn's disease patients. Ann NY Acad Sci 2006, 1091:110-122.
72. Mashayekhi F, Aghahoseini F, Rezaie A, Zamani MJ, Khorasani R, Abdollahi M. Alteration of cyclic nucleotides levels and oxidative stress in saliva of human subjects with periodontitis. J Contemp Dent Pract 2005, 4:046-053.
73. Abdollahi M, Mostafalou S, Pournourmohammadi S, Shadnia S. Oxidative stress and cholinesterase inhibition in saliva and plasma of rats following subchronic exposure to malathion. Comp Biochem Physiol C Toxicol Pharmacol 2004, 137:29-34.
74. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 2004, 49(11-12):1752-7.
75. Astaneie F, Afshari M, Mojtahedi A, Mostafalou S, Zamani MJ, Larijani B, Abdollahi M. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res 2005, 36(4):376-381.
76. Scully C, Felix DH. Oral medicine -update for the dental practitioner: dry mouth and disorders of salivation. Br Dent J 2005, 199(7):423-7.
77. Herrera JL, Lyons MF 2nd, Johnson LF. Saliva: its role in health and disease. J Clin Gastroenterol 1988, 10(5):569-578.
78. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004, 97(1):28-46.
79. Boyce HW, Bakheet MR. Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. J Clin Gastroenterol 2005, 39(2):89-97.
80. Freudenreich O. Drug-induced sialorrhea. Drugs Today (Barc) 2005, 41(6):411-8.
81. Hadjibabaie M, Rastkari N, Rezaie A, Abdollahi M. The adverse drug reaction in the gastrointestinal tract: an overview. Int J Pharmacol 2005, 1(1):1-8.
82. Dehpour AR, Abdollahi M, Alghasi H. Effects of lithium on rat parotid and submandibulary gland functions. Gen Pharmacol 1995, 26(4):851-854.
83. Abdollahi M, Safarhamidi H. Protection by nitric oxide of morphine-induced inhibition of rat submandibular gland function. Pharmacol Res 2002, 45(2):87-92.
84. Abdollahi M, Rahbar-Haghighat M, Soltaninejad K. Prevention by flumazenil of benzodiazepines-suppressed rat submandibular gland function. Ind J Pharmacol 2002, 34:164-171.
85. Abdollahi M, Isazadeh Z. Inhibition of rat parotid and submandibular gland functions by ofloxacin, a fluoroquinolone antibiotic. Fundam Clin Pharmacol 2001; 15(5):307-311.
86. Abdollahi M, Rahmat-Jirdeh N, Soltaninejad K. Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function. Hum Exp Toxicol 2001, 20(1):28-33.
87. Abdollahi M, Dehpour A, Shafayee F. L-arginine/nitric oxide pathway and interaction with lead acetate on rat submandibular gland function. Pharmacol Toxicol 2000, 87(5):198-203.
88. Abdollahi M, Dehpour A, Kazemian P. Alteration by cadmium of rat submandibular gland secretory function and the role of the L-arginine/nitric oxide pathway. Pharmacol Res 2000, 42(6):591-597.
89. Abdollahi M, Dehpour AR, Fooladgar M. Alteration of rat submandibulary gland secretion of protein, calcium and N-acetyl-beta-D-glucosaminidase activity by lead. Gen Pharmacol 1997, 29(4):675-680.
90. Dehpour AR, Shirzad N, Ghafourifar P, Abdollahi M. Effects of cyclosporine A on the functions of submandibular and parotid glands of rats. Gen Pharmacol 1996, 27(5):887-890.
91. Dehpour AR, Ghafourifar P, Massoudi S, Abdollahi M, Mousavizadeh K. On the relation of calcium channel blockers to rat parotid and submandibular glands function in vivo. Gen Pharmacol 1995, 26(3):619-622.
92. Dehpour AR, Ghafourifar P, Madani F, Mousavizadeh K, Abdollahi M. Effects of vinca alkaloids on rat parotid and submandibular glands function in vivo. Gen Pharmacol 1995, 26(2):321-325.
93. Dehpour AR, Abdollahi M. Effects of gentamicin on rat submandibulary gland functions. Gen Pharmacol 1994, 25(8):1719-1722.
94. Ghazi M, Dehpour AR, Abdollahi M, Mortazaiee F. Lead intoxication in rats and its concentrations in blood and saliva. Toxic Subs Mech 1997, 16: 327-385.
95. Abdollahi M, Dehpour AR, Baharnouri G. Alteration by rubidium of rat submandibular secretion of protein and N-acetyl-β-D-glucosaminidase. Toxic Subs Mech 1998, 17:121-131.
96. Abdollahi M, Sharifzadeh M, Marzban H, Abri G, Torab-Jahromi M. Alteration by lead acetate of rats submandibular gland morphology and ultrastructure. Toxic Subs Mech 1999, 18:139-148.
97. Loria RC, Wedner HJ. Facial swelling secondary to inhaled bronchodilator abuse: catecholamine-induced sialadenosis. Ann Allergy 1989, 62(4):289-293.
98. Porter SR, Scully C. Adverse drug reactions in the mouth. Clin Dermatol 2000, 18(5):525-532.
99. Abdollahi M, Minaiee B, Yaaghoubi AA. Structural and functional changes by ciprofloxacin of rat submandibular gland. Hum Exp Toxicol 2003, 22:177-181.
100. Abdollahi M, Simaiee B. Stimulation by theophylline and sildenafil of rat submandibular secretion of protein, epidermal growth factor and flow rate. Pharmacol Res 2003, 48:445-449.
101. Knulst AC, Stengs CJ, Baart de la Faille H, Graamans K, Hene RJ, Collet JT, Bruijnzeel-Koomen CA. Salivary gland swelling following naproxen therapy. Br J Dermatol 1995, 133(4):647-649.
102. Anibarro B, Fontela JL. Sulfadiazine-induced sialadenitis. Ann Pharmacother 1997, 31(1):59-60.
103. Ponte CD. A suspected case of trimipramine-induced salivary adenitis. Drug Intell Clin Pharm 1982, 16(3):248-249.
104. Spolarich AE. Managing the side effects of medications. J Dent Hyg 2000, 74(1):57-69.
105. Browne D, Whelton H, O'Mullane D. Fluoride metabolism and fluorosis. J Dent 2005, 33(3):177-86.
106. Akpata ES. Occurrence and management of dental fluorosis. Int Dent J 2001, 51(5):325-33.
107. Orup HI Jr, Keith DA, Holmes LB. Prenatal anticonvulsant drug exposure: teratogenic effect on the dentition. J Craniofac Genet Dev Biol 1998,18(3):129-37.
108. Reich DR, Bernbaum J, Moskowitz WB. Passive delayed eruption of the primary dentition secondary to Dilantin administration. Report of a case. Oral Surg Oral Med Oral Pathol 1981, 52(6):599-601.
109. Vieillard MH, Maes JM, Penel G, Facon T, Magro L, Bonneterre J, Cortet B. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine 2007, [Epub ahead of print]
110. Levin L, Laviv A, Schwartz-Arad D. Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc 2007, 138(9):1218-20.
111. Malden NJ, Pai AY. Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J 2007, 203(2):93-7.
112. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005, 182(8):417-8.
113. Lam DK, Sandor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007, 73(5):417-22.
114. Clark GT, Ram S. Four oral motor disorders: bruxism, dystonia, dyskinesia and drug-induced dystonic extrapyramidal reactions. Dent Clin North Am 2007, 51(1):225-43.
115. Koc F, Ozeren A. Reversible ageusia associated with clopidogrel treatment. Neurol India 2006, 54(2):218-9.
116. Doty RL, Haxel BR. Objective assessment of terbinafine-induced taste loss. Laryngoscope 2005, 115(11):2035-7.
117. Drew H, Harasty L. Dysgeusia following a course of Zithromax: a case report. J N J Dent Assoc 2007, 78(2):24-7.
118. Ellul P, Vella V, Vassallo M. Reversible dysgeusia attributed to azathioprine. Am J Gastroenterol 2007, 102(3):689.
119. Jaffe IA. Adverse effects profile of sulfhydryl compounds in man. Am J Med 1986, 80(3):471-476.
120. Welge-Lussen A, Gudziol H. [Etiology, diagnostic and therapeutic management of taste disorders] Ther Umsch 2004, 61(5):302-7.
121. Henkin RI. Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. Drug Saf 1994, 11(5):318-77.
122. Scully C, Felix DH. Oral medicine -update for the dental practitioner: oral malodour. Br Dent J 2005, 199(8):498-500.
123. Muzyka BC. Oral fungal infections. Dent Clin North Am 2005, 49(1):49-65.
124. Houston JP, McCollum J, Pietz D, Schneck D. Alveolar osteitis: a review of its etiology, prevention, and treatment modalities. Gen Dent 2002, 50(5):457-63.
125. Torres-Lagares D, Serrera-Figallo MA, Romero-Ruiz MM, Infante-Cossio P, Garcia-Calderon M, Gutierrez-Perez JL. Update on dry socket: a review of the literature. Med Oral Patol Oral Cir Bucal 2005, 10(1):81-5.
126. Bas M, Hoffmann TK, Kojda G. Evaluation and management of angioedema of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2006, 14(3):170-5.
127. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy 2007, 62(8):842-56.
128. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005, 53(3):373-88.
129. Kumar MA, Gupta C. Acquired angioedema secondary to hormone replacement therapy. Indian J Med Sci 2005, 59(10):451-4.
130. Shinkai RS, Hatch JP, Schmidt CB, Sartori EA. Exposure to the oral side effects of medication in a community-based sample. Spec Care Dentist 2006, 26(3):116-20.
131. Moore PA, Gage TW, Hersh EV, Yagiela JA, Haas DA. Adverse drug interactions in dental practice. Professional and educational implications. J Am Dent Assoc 1999, 130(1):47-54.